Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Advances in heart failure therapeutics Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by